You can also add to your health journal encourading news about advances in the stomach cancer management. Here are some of them:
New drug can reduce the risk of developing stomach cancer
A team of scientists from the Technical University of Munich, led by Professor Stefan A. Sieber, in 2026 developed a modified version of the antibiotic Metronidazole, which demonstrated high efficacy against the bacterium Helicobacter pylori, responsible for the development of stomach cancer. This bacterium infects approximately 43% of the world's population. It can cause chronic inflammation of the gastric mucosa, lead to stomach ulcers, and is considered a key risk factor for stomach cancer. In laboratory experiments on mice, the researchers observed a 60-fold increase in efficacy compared to standard Metronidazole, as well as high activity against already resistant bacterial strains. Moreover, the gut microbiome of the mice was less affected than with standard therapy.
New CAR-T immunotherapy increases stomach cancer survival by 40%
Changsong Qi, a professor from the Beijing Cancer Center, presented results from a phase 2 clinical trial of Satri-cel for the treatment of stomach cancer. The treatment is a type of CAR T-cell immunotherapy in which a patient's own immune cells (T cells) are removed, modified to more effectively recognize cancer cells, and then reintroduced into the body. Satri-cel targets a protein called CLDN18.2, which some tumors use to grow. This allows immune cells to more precisely attack cancer cells while sparing healthy tissue. The 2-year trial included 156 patients with stomach or gastroesophageal junction cancer who had failed at least two previous treatments. Patients treated with satri-cel experienced an average 40% increase in survival compared to the control group receiving standard therapy. This significant improvement offers hope to patients with this devastating disease.
Cimetidine could become an over-the-counter cancer drug.
Cimetidine, a well-known and widely used medication for ulcerative and erosive gastrointestinal lesions, may become an over-the-counter treatment for cancer, according to an article published in the popular journal ecancermedicalscience. According to the article's authors, cimetidine may improve patient survival in the treatment of colorectal, stomach, and kidney cancer. Doctors have been studying the drug's effects on cancer for many years. "Cimetidine is an interesting drug because its use is safe, it has been very well studied, and it has demonstrated clinical results in the fight against cancer, which has been confirmed in a number of experiments," says the study's lead author, Pan Pantziarka.